Pneumococcal Vaccination at Age 50 Prevents the Most Disease
Recommending pneumococcal vaccination for all 50-year-olds prevents the most disease in underserved minorities and the general population.
Pneumonia
Legionella Outbreaks on the Rise: Could Climate Change Be Responsible?
Lack of plumbing maintenance; aging infrastructure; warm, humid climates; and exposure to the immunocompromised may contribute to an increase in Legionnaires disease.
Safety and Efficacy of Lefamulin for Treatment of Community-Acquired Pneumonia
A novel antibiotic, lefamulin, may not be inferior to moxifloxacin in efficacy and safety for the treatment of community-acquired bacterial pneumonia.
Rapid Detection of MRSA in Bronchoalveolar Lavage Reduced Antibiotic Use
Use of rapid polymerase chain reaction-based diagnostic tests for MRSA significantly reduced the use of vancomycin and linezolid in patients who were mechanically ventilated with suspected pneumonia at risk for MRSA.
Treatment Efficacy in HABP/VABP: Clinical Endpoints Consensus
Expert opinions on judgment-based criteria for the assessment of antimicrobial treatment efficacy in HABP and VABP are heterogenous.
New Algorithm Identifies Risks in Nosocomial Pneumonia
A new algorithm can search administrative data for individuals with HAP and VAP, who are at significant risk for carbapenem-resistant infection.
Omadacycline Noninferior to Moxifloxacin for Bacterial CAP
A double-blind trial found omadacycline to be noninferior to moxifloxacin for the treatment of community-acquired bacterial pneumonia.
Assessing Pneumococcal Vaccine Immunogenicity in Systemic Lupus Erythematosus
Researchers conducted a post hoc analysis on antipneumococcal antibody responses in patients with SLE previously immunized with the 23-valent pneumococcal polysaccharide vaccine.
Algorithm Developed to Identify Carbapenem Resistance Outcomes in Pneumonia
A novel algorithm has been developed to analyze the epidemiology and outcomes of carbapenem resistance in patients with hospital-acquired and ventilator-associated pneumonia.
FDA to Review IV, Oral Lefamulin for Community-Acquired Bacterial Pneumonia
The FDA has accepted for Priority Review the NDA for intravenous and oral lefamulin for the treatment of CABP.
Next post in Pneumonia
